Nextbiomedical Co (XKRX:389650) EBIT : ₩-6,947 Mil (TTM As of Dec. 2023)

View and export this data going back to 2024. Start your Free Trial

What is Nextbiomedical Co EBIT?

Nextbiomedical Co's earnings before interest and taxes (EBIT) for the six months ended in Dec. 2023 was ₩-6,947 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Dec. 2023 was ₩-6,947 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Nextbiomedical Co's annualized ROC % for the quarter that ended in Dec. 2023 was -11.63%. Nextbiomedical Co's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2023 was -59.98%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Nextbiomedical Co's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 was -2.14%.

Nextbiomedical Co EBIT Historical Data

The historical data trend for Nextbiomedical Co's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Nextbiomedical Co EBIT Chart

Nextbiomedical Co Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

EBIT

-22,942.45

-15,232.24

-5,371.45

-6,947.15

Nextbiomedical Co Semi-Annual Data
	Dec20	Dec21	Dec22	Dec23
EBIT	-22,942.45	-15,232.24	-5,371.45	-6,947.15

Competitive Comparison of Nextbiomedical Co's EBIT

For the Biotechnology subindustry, Nextbiomedical Co's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Nextbiomedical Co's EV-to-EBIT Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Nextbiomedical Co's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Nextbiomedical Co's EV-to-EBIT falls into.

Nextbiomedical Co EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

For stock reported annually, GuruFocus uses latest annual data as the TTM data. EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was ₩-6,947 Mil.

Nextbiomedical Co (XKRX:389650) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Nextbiomedical Co's annualized ROC % for the quarter that ended in Dec. 2023 is calculated as:

	ROC % (Q: Dec. 2023 )
=	NOPAT	/	Average Invested Capital
=	Operating Income * ( 1 - Tax Rate % )	/	( (Invested Capital (Q: Dec. 2022 )	+	Invested Capital (Q: Dec. 2023 ))	/ count )
=	-5226.499 * ( 1 - 0% )	/	( (45162.406	+	44708.429)	/ 2 )
=	-5226.499	/	44935.4175
=	-11.63 %

where

	Invested Capital		(Q: Dec. 2022 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	32135.74	-	420.838	-	( 14797.105	-	max(0, 30968.05	-	17520.546	+	14797.105	))
=	45162.406

	Invested Capital		(Q: Dec. 2023 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	29643.392	-	752.236	-	( 14289.94	-	max(0, 33785.662	-	17968.389	+	14289.94	))
=	44708.429

Note: The Operating Income data used here is one times the annual (Dec. 2023) data.

2. Joel Greenblatt's definition of Return on Capital:

Nextbiomedical Co's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2023 is calculated as:

	ROC (Joel Greenblatt) %		(Q: Dec. 2023 )
=	EBIT	/	Average of (Net fixed Assets	+	Net Working Capital)
=	EBIT	/	Average of (Property, Plant and Equipment	+	Net Working Capital)
			Q: Dec. 2022		Q: Dec. 2023
=	EBIT	/	( ( (Property, Plant and Equipment + Net Working Capital)	+	(Property, Plant and Equipment + Net Working Capital) )	/	count )
=	-6947.145	/	( ( (11735.146 + max(-17979.851, 0))	+	(11427.89 + max(-19782.521, 0)) )	/	2 )
=	-6947.145	/	( ( 11735.146	+	11427.89 )	/	2 )
=	-6947.145	/	11581.518
=	-59.98 %

where Working Capital is:

	Working Capital		(Q: Dec. 2022 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(314.303	+	1940.175	+	298.121)	-	(420.838	+	0	+	20111.612)
=	-17979.851

	Working Capital		(Q: Dec. 2023 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(918.637	+	2168.979	+	376.556)	-	(752.236	+	0	+	22494.457)
=	-19782.521

When net working capital is negative, 0 is used.

Note: The EBIT data used here is one times the annual (Dec. 2023) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Nextbiomedical Co's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %	=	EBIT (TTM)	/	Enterprise Value (Q: Dec. 2023 )
	=	-6947.145	/	323981.978
	=	-2.14 %

Nextbiomedical Co EBIT Related Terms

Thank you for viewing the detailed overview of Nextbiomedical Co's EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

Nextbiomedical Co Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Nextbiomedical Co Ltd (XKRX:389650) » Definitions » EBIT

Comparable Companies

Traded in Other Exchanges

N/A

Address

Venture-ro, No. 6, 100 beongil, Yeonsu-gu, Incheon, KOR

Website

https://www.nextbiomedical.co.kr/kr

Nextbiomedical Co Ltd is an bio-solution company. The company develops and commercializes therapeutic agents for treating diseases based on polymer and drug delivery system technology. The company has developed products that include endoscopic hemostatic agents, vascular embolic microspheres, and others.

Nextbiomedical Co Headlines

No Headlines